Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Among the gram-negative microorganisms with probiotic properties, Escherichia coli strain Nissle 1917 (briefly EcN) is probably the most intensively investigated bacterial strain today. Since nearly 100 years, the EcN strain is used as the active pharmaceutical ingredient in a licensed medicinal product that is distributed in Germany and several other countries. Over the last few decades, novel probiotic activities have been detected, which taken together are specific of this versatile E. coli strain. This review gives a short overview on the discovery and history of the EcN strain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In its unengineered form, EcN has been used to treat various gastrointestinal conditions, including inflammatory bowel disease and irritable bowel syndrome18,19.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [18]
In the citing paper
“Many bacterial species have been evolutionarily selected for metabolic function within the mammalian gastrointestinal tract, and some probiotic organisms have a long history of safe use in humans18,19.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [18]
In the citing paper
“EcN is believed to impede the growth of opportunistic pathogens, including Salmonella spp. and other coliform enteropathogens, through the production of microcin proteins or production of iron-scavenging siderophores18,22,23.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [18]
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Mechanisms of probiotic actions – A review
Oelschlaeger, T. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.08.005 · Cited by 719
Probiotic Bacteria Reduce Salmonella Typhimurium Intestinal Colonization by Competing for Iron
Deriu, E., Liu, J. Z., Pezeshki, M., Edwards, R. A., Ochoa, R. J., Contreras, H., Libby, S. J., Fang, F. C., & Raffatellu, M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.007 · Cited by 550
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482
Wehkamp, J., Harder, J., Wehkamp, K., Meissner, B. W.-V., Schlee, M., Enders, C., Sonnenborn, U., Nuding, S., Bengmark, S., Fellermann, K., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.5750-5758.2004 · Cited by 474
Self-citationZyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U., & Schmidt, M. A. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00836.x · Cited by 428
Self-citationSassone-Corsi, M., & Raffatellu, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403169 · Cited by 328
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
Schultz, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20377 · Cited by 310
Robert Koch and the ‘golden age’ of bacteriology
Blevins, S. M., & Bronze, M. S. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2009.12.003 · Cited by 295
Probiotics: Properties, Examples, and Specific Applications
Behnsen, J., Deriu, E., Sassone-Corsi, M., & Raffatellu, M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a010074 · Cited by 293
Research works printed but not linked: 7
- Geisse, 1919, Behandlung infektiöser Darmerkrankungen mit “Mutaflor”, Ther d Gegenwart, 60, 90
- Loew D . Symposiumsband 4. Interdisziplinäres Symposium Darmflora in Symbiose und Pathogenität – Mikrobiologische Grundlagen und klinische Anwendung von Escherichia coli Stamm Nissle 1917. In: Alfred-Nissle-Gesellschaft e.V. , editor. Leben und Werk von Alfred Nissle. Hagen; 2001. p. 11-9.
- Nissle, 1918, Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien, Med Klin, 2, 29
- Nissle, 1948, Zur Theorie und Praxis der Mutaflortherapie, Hippokrates, 19, 31
- Rörig, 1921, Weiteres über Mutaflor bei Koliinfektion der Harnwege, München Med Wschr, 31, 980
- Ulrich, 1926, Klinische Beobachtungen über Mutaflor bei verschiedenen Erkrankungen, Med Klin, 30, 1152
- Werlé, 1921, Beitrag zur Therapie postdysenterischer Darmstörungen, München Med Wschr, 49, 1581
Cited by
Hiippala, K., Jouhten, H., Ronkainen, A., Hartikainen, A., Kainulainen, V., Jalanka, J., & Satokari, R. (2018) · Nutrients · doi:10.3390/nu10080988 · Cited by 594
“A striking example of this is the Proteobacteria Escherichia coli Nissle 1917 (EcN), which is widely used as a probiotic strain [36].”
BackgroundIsabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Microbiota‐derived extracellular vesicles in interkingdom communication in the gut
Díaz‐Garrido, N., Badia, J., & Baldomà, L. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12161 · Cited by 405
“Concerning intestinal E. coli isolates, the probiotic EcN has been extensively studied due to its recognized immunomodulatory and anti-inflammatory properties that positively contribute tomicrobiota balance (Sonnenborn, 2016; Sonnenborn& Schulze, 2009; Toloza et al., 2015).”
BackgroundInteraction of the microbiota with the human body in health and diseases
ALTVEŞ, S., YILDIZ, H. K., & VURAL, H. C. (2020) · Bioscience of Microbiota, Food and Health · doi:10.12938/bmfh.19-023 · Cited by 389
“coli and used it to treat shigellosis [92].”
Background
Metadata
- Authors
- Sonnenborn, U.
- Affiliations
- Ardeypharm (Germany) (DE)
- Corresponding author
- Sonnenborn, Ulrich
- Venue
- FEMS Microbiology Letters
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-11
- Volume
- 363
- Issue
- 19
- Pages
- fnw212
- ISSN
- 0378-1097 (ISSN-L)
- 1574-6968
- OpenAlex
- W2520661070
- Cited by
- 315
- References
- 34
- Citations by year
- 2026: 44 · 2025: 38 · 2024: 49 · 2023: 39 · 2022: 42 · 2021: 39 · 2020: 28 · 2019: 21 · 2018: 12 · 2017: 3
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- FEMS Microbiology Letters (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- probiotics, history of probiotics, probiotic activity
- MeSH terms
- Gastrointestinal Microbiome, Antibiosis, Escherichia coli, Germany, Humans, Probiotics, Gastrointestinal Tract, History, 20th Century, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. https://app.cochat.ai/papers/10.1093/femsle/fnw212
- The paper
- Sonnenborn, U. (2016). Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiology Letters. https://doi.org/10.1093/femsle/fnw212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.